A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
for Generalized Myasthenia Gravis
Drug: Iptacopan
21 locations incl. Scottsdale
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 18 - 85
Code: NCT06517758·Phase 3·Recruiting